

INFORMATION DISCLOSURE  
CITATION

PTO-1449

ATTY. DOCKET NO.  
A-65182-1/RFT/JJDSERIAL NO.  
09/712,028APPLICANT  
Patterson et al.FILING DATE  
November 13, 2000GROUP  
1619RECEIVED  
OCT 19 2001  
TECH CENTER 1600/2500  
FILING DATE

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	
RLS	1	5,344,644	09/1994	Igari et al.	424	85-1	1
	2	5,416,071	05/1995	Igari et al.	514	8	1
	3	5,639,275	06/1997	Baetge et al.	604	891.1	1
RLS	4	5,427,925	06/1995	Gearing et al.	435	69.5	1
	5	5,187,077	02/1993	Gearing et al.	435	69.1	1
	6	5,443,825	08/1995	Gearing et al.	424	85.1	1
RLS	7	5,750,654	05/1998	Gearing et al.	530	351	1

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RLS	8	Patterson, "Leukemia inhibitory factor, a cytokine at the interface between neurobiology and immunology," <i>Proc Natl Acad Sci U.S.A.</i> 91:7833-7835 (August 1994).					
	9	Alexander et al., "D-Factor/Leukaemia Inhibitory Factor: Evidence for its Role as a Mediator in Acute and Chronic Inflammatory Disease," <i>Cytokine</i> , 6(6):589-596 (November 1994).					
	10	Brown et al., "Leukaemia Inhibitory Factor and Interleukin 6 Are Expressed at Very Low Levels in the Normal Adult Mouse and Are Induced by Inflammation," <i>Cytokine</i> , 6(3):300-309 (May 1994).					
	11	Ulrich et al., "Intratracheal injection of LPS and cytokines: V. LPS induces expression of LIF and LIF inhibits acute inflammation," <i>Amer J Physiol</i> , L442-L446 (1994).					
	12	Heymann et al., "Leukaemia Inhibitory Factor (LIF) Production in Pleural Effusions: Comparison with production of IL-4, IL-8, IL-10 and Macrophage-Colony Stimulating Factor (M-CSF)," <i>Cytokine</i> , 8(5):410-416 (May 1996)					
RLS	13	Kurek et al., "UP-Regulation of Leukaemia Inhibitory Factor and Interleukin-6 in Transected Sciatic Nerve and Muscle Following Denervation," <i>Neuromuscle Disorders</i> , 6(2):105-114 (1996)					

EXAMINER

RLS

DATE CONSIDERED

10/23/02

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant

X 88-111 (REV. 8-75) 1-2284

## INFORMATION DISCLOSURE CITATION

PTO-1449

ATTY. DOCKET NO.  
A-65182-1/RFT/JJDSERIAL NO.  
09/712,028APPLICANT  
Patterson et al.FILING DATE  
November 13, 2000GROUP  
1619

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RRS	14	Banner et al., "Leukemia Inhibitory Factor Is Expressed in Astrocytes Following Cortical Brain Injury," <i>Exper. Neurol.</i> 147:1-9 (1997).
	15	Rao et al., "Leukemia Inhibitory Factor Mediates an Injury Response but Not a Target-Directed Developmental Transmitter Switch in Sympathetic Neurons," <i>Neuron</i> , 11:1175-1185 (December 1993).
	16	Corness et al., "Influence of leukemia inhibitory factor on galanin/GMAP and neuropeptide Y expression in mouse primary sensory neurons after axotomy," <i>Exp Brain Res</i> , 112:79-88 (1996).
	17	Tham et al., "Leukemia Inhibitory Factor Enhances the Regeneration of Transected Rat Sciatic Nerve and the Function of Reinnervated Muscle," <i>J. Neurosci. Res.</i> 47:208-215 (1997).
	18	Banner et al., "Leukemia Inhibitory Factor Is an Anti-Inflammatory and Analgesic Cytokine," <i>J. Neurosci.</i> 18(14):5456-5462 (July 15, 1998).
	19	Sun and Zigmond, "Leukaemia inhibitory factor induced in the sciatic nerve after axotomy is involved in the induction of galanin in sensory neurons," <i>Eur. J. Neurosci.</i> 1996 Oct.8(10):2213-20.
	20	Sugiura, et al., "Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro," (2000) <i>Eur. J. Neurosci.</i> 12: 457-466
	21	Tofaris, et al., "Schwann cells deprived of axonal contact produce the chemoattractants MCP-1 and LIF, which are regulated by autocrine circuits involving LIF and IL-6," in Society for Neuroscience 30th Annual Meeting, New Orleans, LA, 2000; Abstract: 4-9 November 2000
	22	Sendtner, et al., "Cryptic physiological trophic support of motoneurons by LIF revealed by double gene targeting of CNTF and LIF," (1996) <i>Curr Biol</i> 6:686-694
	23	Ullrich, S.E., "The role of epidermal cytokines in the generation of cutaneous immune reactions and ultraviolet radiation-induced immune suppression," (1995) <i>Photochem. Photobiol.</i> 62(3):389-401
	24	Asadullah, et al., "The pathophysiological role of cytokines in psoriasis," (1999) <i>Drugs Today</i> 35(12):913-924
	25	Bonifati, et al., "Cytokines in psoriasis," (Apr 1999) <i>Int. J. Dermat.</i> 38(4):241-51
	26	Corsini, et al., "Epidermal cytokines in experimental contact dermatitis," (Jan 2000) <i>Toxicology</i> 142(3):203-11
	27	Naik, et al., "Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene," (Nov 1999) <i>J. Invest. Dermatol.</i> 113(5):766-72
	28	Asadullah, et al., "IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach," (Feb 1998) <i>J. Clin. Invest.</i> 101(4):783-94
	29	Trepicchio, et al., "Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions (Dec 1999) <i>J. Clin. Invest.</i> 104(11):1527-37
	30	Gadient, et al., "Leukemia inhibitory factor, Interleukin 6, and other cytokines using the Gp130 transducing receptor roles in inflammation and injury," (1999) <i>Stem Cells</i> 17(3):127-37
RRS	31	Carroll, et al., "Leukemia inhibitory factor induces leukocyte infiltration and cartilage proteoglycan degradation in goat joints," (Jun 1995) <i>J. Interferon. Cytokine Res.</i> 15(6):567-73


EXAMINER

RRS

DATE CONSIDERED

10/23/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
OCT 19 2001  
TECH. CENTER 1600/2900  
SHEET 3 of 4

# INFORMATION DISCLOSURE CITATION

PTO-1449

ATTY. DOCKET NO.  
A-65182-1/RFT/JJD

SERIAL NO.  
09/712,028

APPLICANT  
Patterson et al.

FILING DATE  
November 13, 2000

GROUP  
1619

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RPS	32	McKenzie, et al., "A novel endogenous mediator of cutaneous inflammation: leukemia inhibitory factor," (Mar 1996) <i>Acta Derm. Venereol. (Stockh)</i> 76(2):111-4
	33	Thompson, et al., "Leukemia inhibitory factor induces mechanical allodynia but not thermal hyperalgesia in the juvenile rat," (Apr 1996) <i>Neuroscience</i> 71(4):1091-4
	34	Inoue, et al., "Activating mechanism of CNTF and related cytokines," <i>Mol Neurobiol.</i> (Jun 1996) 12(3):195-209
	35	Dinarello, C.A., "Biologic basis for interleukin-1 in disease," <i>Blood</i> (Mar 1996) 87(6):2095-147
	36	Campbell et al., "Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor alpha," <i>Arthritis Rheum.</i> (Jun 1993) 36(6):790-4
	37	Lorenzo et al., "Tumor necrosis factor alpha stimulates production of leukemia inhibitory factor in human dermal fibroblast cultures," <i>Clin Immunol Immunopathol.</i> (Mar 1994) 70(3):260-5
	38	Jansen et al., "Release of leukemia inhibitory factor in primate sepsis. Analysis of the role of TNF-alpha," <i>J Immunol.</i> (Jun 1996) 156(11):4401-7
	39	Sato et al., "Regulatory role of endogenous interleukin-10 in cutaneous inflammatory response of murine wound healing," <i>Biochem Biophys Res Commun.</i> (Nov 1999) 265(1):194-9
	40	Groves et al., "Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis," <i>Proc Natl Acad Sci U S A</i> (Dec 1995) 92(25):11874-8
	41	Schmitt et al., "Effect of IL-12 on immune suppression and suppressor cell induction by ultraviolet radiation," <i>J Immunol.</i> (May 1995) 154(10):5114-20
	42	Saloga et al., "Active suppression induced by cutaneous exposure to bacterial superantigen is prevented by interleukin-12 treatment in vivo," <i>Immunology.</i> (Apr 1998) 93(4):485-92
	43	Enk et al., "An essential role for Langerhans cell-derived IL-1 beta in the initiation of primary immune responses in skin," <i>J Immunol.</i> (May 1993) 150(9):3698-704
	44	Bonifati et al., "Increased interleukin-7 concentrations in lesional skin and in the sera of patients with plaque-type psoriasis," <i>Clin Immunol Immunopathol.</i> (Apr 1997) 83(1):41-4
	45	Dieli et al., "gamma delta cells involved in contact sensitivity preferentially rearrange the Vgamma3 region and require interleukin-7," <i>Eur J Immunol.</i> (Jan 1997) 27(1):206-14
	46	Samaridis et al., "Development of lymphocytes in interleukin 7-transgenic mice," <i>Eur J Immunol.</i> (Feb 1991) 21(2):453-60
	47	Uehira et al., "Immunologic abnormalities exhibited in IL-7 transgenic mice with dermatitis," <i>J Invest Dermatol.</i> (May 1998) 110(5):740-5
	48	Mertsching et al., "IL-7 transgenic mice: analysis of the role of IL-7 in the differentiation of thymocytes in vivo and in vitro," <i>Int Immunol.</i> (Mar 1995) 7(3):401-14
	49	Williams et al., "IL-7 overexpression in transgenic mouse keratinocytes causes a lymphoproliferative skin disease dominated by intermediate TCR cells: evidence for a hierarchy in IL-7 responsiveness among cutaneous T cells," <i>J Immunol.</i> (Sep 1997) 159(6):3044-56
	50	Nishimura et al., "Defective immune response and severe skin damage following UVB irradiation in interleukin-6-deficient mice," <i>Immunology.</i> (May 1999) 97(1):77-83
RPS	51	Bonifati et al., "Spontaneous release of leukemia inhibitory factor and oncostatin-M is increased in supernatants of short-term organ cultures from lesional psoriatic skin," <i>Arch Dermatol Res.</i> (Jan-Feb 1998) 290(1-2):9-13

EXAMINER

RPS

DATE CONSIDERED

10/23/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449

SERIAL NO.  
09/712,028

APPLICANT  
Patterson et al.

FILING DATE  
November 13, 2000

GROUP  
1619

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

[illegible]

EXAMINER

DATE CONSIDERED

10/23/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

8085 1443A FRM 9 35